Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Trevi Therapeutics, Inc. (TRVI)

Trevi reports Q2 2026 net loss of $17.8 million, up from $12.3 million

Negative Impact 3 of 5 earnings Written later

Trevi Therapeutics reported a second-quarter 2026 net loss of $17.8 million, or $0.11 per share, compared with a net loss of $12.3 million, or $0.09 per share, a year earlier. Research and development and general and administrative spending both rose, and the company ended the quarter with $318.9 million in cash, cash equivalents and marketable securities after an April 2026 stock offering, which it says extends its cash runway into 2030.

Key points

  • Net loss for Q2 2026 was $17.8 million, versus $12.3 million in Q2 2025; loss per share was $0.11 versus $0.09.
  • R&D expenses rose to $15.2 million from $9.4 million, mainly due to Phase 3 OCEAN-1, Phase 2b LAKE and Phase 3 OCEAN-2 trial costs.
  • G&A expenses rose to $5.4 million from $4.3 million, driven by stock-based compensation and personnel costs.
  • Cash, cash equivalents and marketable securities were $318.9 million at June 30, 2026; the April 2026 offering brought in net proceeds of about $162.3 million.

The filing

CompanyTrevi Therapeutics, Inc. (TRVI)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:08 PM ET
Accession number0001193125-26-337974

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.